

FORM PTO-1449

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
1488.1220001/EKS/PAJAPPLICATION NO.
09/518,383FIRST NAMED INVENTOR
Li et al.FILING DATE
March 3, 2000ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
PM	AE1 2002/0052043 A1	05/02/2002	Li et al.	MAR 1 2004		04/09/2001
AF						
AG						
AH						
AI						
AJ						
AK						


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
PM	AN1 WO 91/15583 A1	10/17/1991	WIPO			Yes No
PM	AO1 WO 99/35106 A2	07/15/1999	WIPO			Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR			
PM	AS 4		Chattaraj, S.C., "Cangrelor AstraZeneca," <i>Curr. Opin. Invest. Drugs</i> 2:250-255, PharmaPress Ltd. (February 2001)
PM	AT 4		Van Brocklyn, J.R., et al., "Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6," <i>Blood</i> 95:2624-2629, The American Society of Hematology (April 2000)

EXAMINER	Prema Meny	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		



FORM PTO-1449

~~NOTICE OF~~ SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.

1488.1220001/EKS/PAJ

APPLICATION NO.

09/518,383

FIRST NAMED INVENTOR

Li et al.

FILING DATE

March 3, 2000

ART UNIT

1646

Page 2 of 3

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						MAR 01 2004
AF						
AG						
AH						
AI						
AJ						
AK						


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes
AM						No
AN						Yes
AO						No
AP						Yes
						No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

PM	AR	5	Wang, K., et al., "Blockade of the Platelet P2Y12 Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model," <i>Arterioscler. Thromb. Vasc. Biol.</i> 22:357-362, Lippincott, Williams & Wilkins (February 2003)
PM	AS	5	Database EMBL, Accession No. AA254425, Marra, M., et al., (first available March 1997)
PM	AT	5	Partial European Search Report for European Application No. 03 01 5456, mailed December 17, 2003, European Patent Office, Netherlands

EXAMINER	Premal Mehta	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		



FORM PTO-1449

~~EXAMINER'S~~ SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
1488.1220001/EKS/PAJAPPLICATION NO.
09/518,383FIRST NAMED INVENTOR
Li et al.FILING DATE
March 3, 2000ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

MAR 01 2004

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes
AM						No
AN						Yes
AO						No
AP						Yes

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

PM	AR	6	Copy of Co-Pending U.S. Patent Application No. 09/518,381, Li et al., filed March 3, 2000 (NOT PUBLISHED)
	AS		
	AT		

EXAMINER

Prerna Mank

DATE CONSIDERED

9/22/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.